Related Experiment Video
Updated: Jun 26, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism
Chung-Wah Siu1, Vincent Pong, Xuehua Zhang
1Cardiology Division, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China.
Insights
Hyperthyroidism-induced atrial fibrillation (AF) increases ischemic stroke risk, especially early after diagnosis. Early anticoagulation therapy is crucial for these patients.
Area of Science:
- Cardiology
- Endocrinology
- Neurology
Background:
- Hyperthyroidism is a common, reversible cause of atrial fibrillation (AF).
- The specific risk of ischemic stroke in new-onset AF associated with hyperthyroidism remains unclear.
- Understanding this risk is critical for patient management.
Purpose of the Study:
- To investigate the clinical outcomes, focusing on ischemic stroke risk.
- To compare hyperthyroidism-induced AF with non-thyroid AF and hyperthyroid patients without AF.
- To identify predictors of ischemic stroke in this population.
Main Methods:
- Prospective study of 160 patients with hyperthyroidism-induced AF.
- Comparison with age- and sex-matched cohorts: 160 hyperthyroid patients without AF and 160 AF patients without hyperthyroidism.
- Analysis of incidence, time course, and predictors of ischemic stroke over 1 year.
Main Results:
- Ischemic stroke occurred in 9.4% of hyperthyroid AF patients vs. 3.1% of non-thyroid AF patients (P = .02).
- Over 70% of strokes in AF patients occurred within 30 days of presentation.
- Hyperthyroidism (HR: 3.5) and persistent AF (HR: 13.0) predicted stroke; warfarin reduced risk (HR: 0.17).
Conclusions:
- Patients with new-onset AF due to hyperthyroidism face an elevated ischemic stroke risk.
- This risk is concentrated in the initial presentation period.
- Prompt initiation of anticoagulation therapy is recommended for hyperthyroid patients with AF.
Background:
Hyperthyroidism is one of the most common reversible causes of atrial fibrillation (AF); nevertheless, the risk of ischemic stroke in patients with hyperthyroidism who present with new-onset AF is unclear.
Objective:
This study sought to investigate the clinical outcome of hyperthyroidism-induced AF with regard to risk of ischemic stroke risk.
Methods:
We prospectively studied the incidence, time course, and clinical predictors for ischemic stroke in patients with hyperthyroidism-induced AF (n = 160). They were compared with age- and sex-matched cohorts of hyperthyroid patients without AF (n = 160) and AF patients without hyperthyroidism (n = 160).
Results:
Baseline characteristics were comparable among the 3 groups. At 1 year, 86 hyperthyroid patients with AF (54%) and 92 patients with nonthyroid AF (58%) had spontaneous or pharmacological sinus conversion (P = .20). Ischemic stroke was observed in 15 hyperthyroid patients with AF (9.4%) versus 5 patients with nonthyroid AF (3.1%, P = .02), and 1 hyperthyroid patient without AF (0.6%, P < .001). Furthermore, the majority of ischemic stroke (>70%) in patients with AF occurred within the first 30 days of presentation, whereas AF was still present. Cox regression analysis showed that hyperthyroidism (hazard ratio [HR]: 3.5, 95% confidence interval [CI]: 1.15 to 10.42, P = .03) and persistent AF (HR: 13.0, 95% CI: 2.88 to 58.80, P < .01) predicted the occurrence of ischemic stroke; warfarin therapy reduced the risk of ischemic stroke (HR: 0.17, 95% CI: 0.04 to 0.79, P = .02).
Conclusion:
In hyperthyroid patients who presented with new-onset AF, there was an increased risk of ischemic stroke clustering during the initial phase of presentation. This should prompt early use of anticoagulation therapy in hyperthyroid patients with AF.
Related Concept Videos
Hyperthyroidism II: Pathophysiology
Hyperthyroidism I: Introduction
Graves' Disease I: Introduction
Dysrhythmias II: Classification of Tachyarrhythmias
Graves Disease II: Pathophysiology
Hypothyroidism II: Pathophysiology
